Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)
CompletedOBSERVATIONAL
Enrollment
15
Participants
Timeline
Start Date
August 18, 2015
Primary Completion Date
May 10, 2018
Study Completion Date
May 10, 2018
Conditions
Acute Myeloid Leukemia
Trial Locations (1)
20892
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
All Listed Sponsors
lead
National Heart, Lung, and Blood Institute (NHLBI)
NIH
NCT02527447 - Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15) | Biotech Hunter | Biotech Hunter